Unicancer
Clinical trials sponsored by Unicancer, explained in plain language.
-
New combo may extend life in tough pancreatic cancer
Disease control CompletedThis study looked at 211 people with advanced pancreatic cancer whose first treatment (FOLFIRINOX) stopped working or caused too many side effects. Researchers compared a two-drug combination (gemcitabine and paclitaxel) against gemcitabine alone to see if the combo helped people…
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New chemo cocktail tested to prevent colon cancer return
Disease control CompletedThis study tested whether a stronger chemotherapy combination (mFOLFIRINOX) works better than the standard one (mFOLFOX) for people with high-risk stage III colon cancer after surgery. About 792 patients took part across multiple countries. The goal was to see if the stronger com…
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Immunotherapy combo shows promise for inoperable esophageal cancer
Disease control CompletedThis Phase 2 trial tested whether adding the immunotherapy drug durvalumab to standard chemoradiation (FOLFOX and radiation) helps patients with unresectable esophageal cancer. 112 patients were randomly assigned to receive either chemoradiation alone or chemoradiation plus durva…
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New hope for liver cancer patients with damaged livers?
Disease control CompletedThis study tested a drug called tislelizumab in 50 people with advanced liver cancer who also have moderate liver damage (Child-Pugh B). The goal was to see if the drug could shrink tumors. Tislelizumab works by helping the immune system attack cancer cells. The study took place …
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Gene test guides breast cancer treatment switch in major trial
Disease control CompletedThis study tested a new strategy for people with a common type of advanced breast cancer (ER+, HER2-). It used a blood test to look for a gene change (ESR1 mutation) that can make cancer stop responding to the first hormone therapy. When the mutation appeared, some patients switc…
Phase: PHASE3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Virtual planning may improve quality of life after jaw reconstruction
Symptom relief CompletedThis study tested whether using computer-based virtual planning before jaw reconstruction surgery improves patients' quality of life compared to standard surgery. 132 adults with oral or oropharyngeal cancer who needed a fibula free-flap reconstruction took part. The main goal wa…
Phase: NA • Sponsor: UNICANCER • Aim: Symptom relief
Last updated Jun 27, 2026 07:59 UTC
-
Older breast cancer patients given a say in skipping or shortening radiation
Knowledge-focused CompletedThis study looked at how women aged 65 and older with early-stage breast cancer choose among three options after surgery: standard weeks-long whole-breast radiotherapy, a single dose of radiation during surgery, or no radiation at all. Researchers surveyed 104 patients to underst…
Phase: NA • Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC